Research from Wyndham H. Wilson et al. Showed that ibrutinib with R-CHOP could increase event-free survival (EFS) of patients with MCD DLBCL from 48% to 69.6% [160]. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.